Priveterra Acquisition Adjourns Aeon Merger Vote for the 5th Time

Priveterra Acquisition in an 8-K said its rescheduled shareholder meeting to vote on the proposed merger with Aeon Biopharma will now be adjouned until June 26 at noon Eastern time. This is the fifth postponement in the last two weeks. As with the previous postponements, the latest is “to allow additional time for the company to engage with its stockholders,” Priveterra said in the filing.

Stockholders who wish to withdraw their redemption request may still do so prior to the rescheduled meeting.

Priveterra in April lowered the minimum cash closing condidition to $40 million from the initial $45 million. The expense cap for Priveterra was increased by $300,000 to $10.3 million.

Terms also allow either party to terminate the deal if it does not close by July 31.

AEON is a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions.

Total
0
Shares
Related Posts
Roth Ch Acquisition II
Read More

SPAC Target Reservoir Holdings Buying Music Label for $100M

Roth CH Acquisition II in an 8-K filing said that its merger partner Reservoir Holdings has agreed to purchase U.S. based record label and music publishing company Tommy Boy Music for $100 million. The Roth/Reservoir deal has an enterprise value of $788 million, the parties said in April. Existing Reservoir owners will roll 100 percent of their equity into the combined enterprise.